| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0826 | ay-30068 | Cyclooxygenase Inhibitor; |
|
| DCC0827 | az1136 | Second Generation |
|
| DCC0828 | Az11760788 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0829 | Az12048189 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0830 | Az12080282 Dihydrochloride | Novel orally bioavailable inhibitor of Hedgehog signaling |
|
| DCC0831 | Az12099548 | Novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist |
|
| DCC0832 | Az12489875-002 | Novel potent EphB4 inhibitor |
|
| DCC0833 | Az1366 | Novel tankyrase inhibitor, enhancing irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance |
|
| DCC0834 | Az-13767370 | Novel covalent ERK1/2 inhibitor |
|
| DCC0835 | Az7188 | Novel weak PAR2 antagonist |
|
| DCC0836 | Aza197 | Novel selective Cdc42 inhibitor, suppressing primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity |
|
| DCC0837 | aza-bodipy | Near-IR probe for detecting conformational changes of Aβ1-42 soluble oligomers in vitro |
|
| DCC0838 | azadirone | Inducer of Death Receptors and Sensitizer of Human Cancer Cells to TRAIL through a p53-Independent Mechanism |
|
| DCC0839 | Azalanstat | Inhibitor of hepatic cholesterol biosynthesis, inhibiting the cytochrome P450 enzyme lanosterol 14alpha-demethylase |
|
| DCC0840 | Aza-thip | Novel selective GABA-C antagonist |
|
| DCC0841 | Azd Cxcr2 Antagonist | Novel CXCR2 antagonist with 200 times improvement in solubility than AZD8309 |
|
| DCC0842 | Azd0328 | Selective alpha7 nicotinic receptor activator |
|
| DCC0843 | Azd1386 | Novel transient receptor potential vanilloid 1 (TRPV1) antagonist |
|
| DCC0844 | Azd1897 Featured | AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways. |
|
| DCC0845 | Azd4619 | Novel peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, inducing alanine aminotransferase-1 gene and protein expression in human, but not in rat hepatocytes |
|
| DCC0846 | Azd4996 | Novel potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis |
|
| DCC0847 | Azd5438-protac-8 | First-in-class selective, partial CDK2 degrader against hearing loss and cancer, protecting against cisplatin ototoxicity and kainic acid excitotoxicity |
|
| DCC0848 | Azd6370 | Glucokinase activator, decreasing fasting and postprandial glucose in type 2 diabetes mellitus patients |
|
| DCC0849 | Azd6564 | Novel Fibrinolysis Inhibitor, Acting via Interference of a Protein-Protein Interaction |
|
| DCC0850 | Azd6642 | Novel selective inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the treatment of inflammatory diseases |
|
| DCC0851 | Azd6703 | Novel, potent and selective inhibitor of p38α MAP kinase |
|
| DCC0852 | Azd7254 | Novel potent smoothened inhibitor, demonstrating in vivo activity in abrogating the Hh paracrine pathway as well as anti- tumor effects |
|
| DCC0853 | Azd9742 | Antimicrobials, active against methicillin resistant S. aureus (MRSA) |
|
| DCC0854 | Az-dyrk1b-33 | Potent and selective ATP-competitive Dyrk1B kinase inhibitor |
|
| DCC0855 | Azelastine | Potent, second-generation, selective histamine-H1-receptor antagonist and mast cell stabilizer |
|
